VolitionRx Completes Validation of Nu.Q Vet Cancer Test
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 06 2026
0mins
Should l Buy VNRX?
VolitionRx announces the completion of all validation and verification of the chemiluminescent immunoassay version of its Nu.Q Vet Cancer Test with Fujifilm Vet Systems Co. in Japan, allowing use of full automation rather than manual plates in central laboratories. Volition's supply agreement enables Fujifilm Vet Systems to sell and perform the Nu.Q Vet Cancer Test throughout its network of central reference laboratories in Japan.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy VNRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on VNRX
Wall Street analysts forecast VNRX stock price to rise
3 Analyst Rating
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 0.201
Low
1.50
Averages
2.25
High
3.00
Current: 0.201
Low
1.50
Averages
2.25
High
3.00
About VNRX
VolitionRx Limited is a multi-national company focused on advancing the science of epigenetics. The Company is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its key pillars are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer, and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
VolitionRx Achieves Breakthrough with New Liquid Biopsy Method
- New Cancer Detection Method: VolitionRx announced that its new liquid biopsy method achieved over 95% sensitivity and specificity for stage I and II cancers during a blinded validation cohort, marking a significant advancement in early cancer detection that could enhance its market competitiveness.
- Stock Price Surge: Following this announcement, VolitionRx shares surged more than 34% in pre-market trading on Wednesday, reflecting strong investor confidence in the company's new technology and a positive market reaction that may attract further investor interest.
- Optimistic Market Sentiment: According to data from Stocktwits, retail sentiment around VolitionRx trended bullish, with message volumes at extremely high levels, indicating strong market recognition of its new technology and active investor participation, potentially driving further stock price increases.
- Future Growth Potential: As liquid biopsy technology continues to mature, VolitionRx is poised to capture a larger share of the cancer detection market, particularly in early diagnosis, which will provide the company with long-term growth opportunities and strategic advantages.
See More
VolitionRx's Breakthrough Liquid Biopsy Technology Achieves High Detection Rates
- Technological Breakthrough: VolitionRx's Capture-Seq liquid biopsy technology successfully detected over 95% of stage I and II cancers in a blinded validation, showcasing its immense potential in multi-cancer early detection and addressing the urgent market need for early diagnosis.
- Significant Detection Rates: Among 81 participants, Capture-Seq achieved a 94% detection rate for stage I cancers and 96% for stage II, with an overall sensitivity of 93% and a specificity of 95% among healthy controls, laying a solid foundation for future clinical applications.
- Broad Market Potential: VolitionRx estimates a total addressable market of approximately $23 billion for human multi-cancer early detection and over $13 billion for minimal residual disease applications, highlighting the commercial viability and attractiveness of this technology.
- Increased Collaboration Opportunities: The company is in discussions with several major liquid biopsy and diagnostic firms to accelerate development and commercialization, with Capture-Seq's strong results generating significant interest from potential licensing partners.
See More
VNRX Shares Jump 34% in Pre-Market Trading — What’s Fueling the Surge?
VolitionRx Share Price Drop: VolitionRx (VNRX) shares fell over 34% in pre-market trading following the announcement of proof-of-concept data from a blinded validation cohort for cancer detection.
New Liquid Biopsy Method: The company revealed a new liquid biopsy method that achieved over 95% sensitivity for stage I & II cancers, with 95% specificity during the blinded validation cohort.
Retail Sentiment: Retail sentiment around VolitionRx trended bullish, with message volumes reported at extremely high levels at the time of writing.
Updates and Corrections: For ongoing updates and corrections related to this story, readers are encouraged to check Stocktwits.
See More
VolitionRx Shares Surge 70% on Breakthrough in Cancer Detection
- Stock Surge: VolitionRx (VNRX) shares soared over 70% in pre-market trading on Wednesday, reflecting strong market enthusiasm for its breakthrough in cancer detection, with the stock poised to breach its 100-day moving average for the first time since October 8, 2025.
- Technological Innovation: The company successfully isolated over 99% pure circulating tumor-derived DNA (ctDNA) from blood samples of cancer patients, addressing a key challenge in liquid biopsy where most circulating DNA typically originates from healthy cells.
- New Method Announcement: VolitionRx submitted an updated manuscript detailing a new two-step method that combines physical sample enrichment with advanced bioinformatics to remove nearly all non-cancer DNA, marking a significant scientific breakthrough in cancer testing and monitoring.
- Scientific Discovery: Chief Scientific Officer Jake Micallef stated that there is almost no CTCF-bound DNA in healthy plasma, and nearly all CTCF-bound DNA in cancer patients' blood is derived from cancer cells, which could represent the biggest scientific breakthrough in cancer testing in recent years.
See More
VolitionRx Unveils New Cancer Detection Technology
- Technological Breakthrough: VolitionRx has successfully isolated and analyzed over 99% pure circulating tumor-derived DNA (ctDNA), a world-first achievement that could revolutionize the liquid biopsy field by enhancing the accuracy and efficiency of early cancer detection.
- Market Potential: The company anticipates a total addressable market (TAM) of approximately $36 billion in multi-cancer early detection (MCED) and minimal residual disease (MRD), indicating significant commercial opportunities and market demand.
- Clinical Validation: The CTCF Capture-Seq™ technology detected 49 cancer cases with no false positives in two independent validation cohorts, showcasing its immense potential in early cancer detection and possibly improving disease management for patients.
- Partnership Opportunities: VolitionRx is actively engaging with several large liquid biopsy and diagnostic companies to accelerate the development and commercialization of this technology, which is expected to enhance the company's competitiveness in the rapidly evolving cancer detection market.
See More
VolitionRx Completes Validation of Nu.Q® Vet Cancer Test with Fujifilm
- Automation Breakthrough: VolitionRx has completed the validation of its Nu.Q® Vet Cancer Test in collaboration with Fujifilm Vet Systems, enabling full automation in central laboratories, which significantly enhances testing efficiency and is expected to meet the increasing demand in the Japanese market.
- Significant Market Potential: Since its launch in July 2024, over 1,700 veterinary hospitals have registered to use the test, indicating a strong demand among Japanese veterinarians for early cancer detection, which is anticipated to create substantial revenue opportunities for Volition.
- Synergistic Technology Platform: The test operates on the same Immunodiagnostic Systems i10® automated analyzer platform used for Volition's human products, showcasing the synergy between human and animal diagnostic technologies, thereby strengthening the company's competitive position in the market.
- Importance of Early Detection: Cancer is the leading cause of death in adult dogs, and the Nu.Q® Vet Cancer Test serves as an accessible and affordable screening tool that aids in early detection, improving health outcomes for dogs, aligning with Volition's mission to enhance life quality through early diagnosis.
See More
VolitionRx Achieves Breakthrough with New Liquid Biopsy Method
- New Cancer Detection Method: VolitionRx announced that its new liquid biopsy method achieved over 95% sensitivity and specificity for stage I and II cancers during a blinded validation cohort, marking a significant advancement in early cancer detection that could enhance its market competitiveness.
- Stock Price Surge: Following this announcement, VolitionRx shares surged more than 34% in pre-market trading on Wednesday, reflecting strong investor confidence in the company's new technology and a positive market reaction that may attract further investor interest.
- Optimistic Market Sentiment: According to data from Stocktwits, retail sentiment around VolitionRx trended bullish, with message volumes at extremely high levels, indicating strong market recognition of its new technology and active investor participation, potentially driving further stock price increases.
- Future Growth Potential: As liquid biopsy technology continues to mature, VolitionRx is poised to capture a larger share of the cancer detection market, particularly in early diagnosis, which will provide the company with long-term growth opportunities and strategic advantages.
See More
VolitionRx's Breakthrough Liquid Biopsy Technology Achieves High Detection Rates
- Technological Breakthrough: VolitionRx's Capture-Seq liquid biopsy technology successfully detected over 95% of stage I and II cancers in a blinded validation, showcasing its immense potential in multi-cancer early detection and addressing the urgent market need for early diagnosis.
- Significant Detection Rates: Among 81 participants, Capture-Seq achieved a 94% detection rate for stage I cancers and 96% for stage II, with an overall sensitivity of 93% and a specificity of 95% among healthy controls, laying a solid foundation for future clinical applications.
- Broad Market Potential: VolitionRx estimates a total addressable market of approximately $23 billion for human multi-cancer early detection and over $13 billion for minimal residual disease applications, highlighting the commercial viability and attractiveness of this technology.
- Increased Collaboration Opportunities: The company is in discussions with several major liquid biopsy and diagnostic firms to accelerate development and commercialization, with Capture-Seq's strong results generating significant interest from potential licensing partners.
See More
VNRX Shares Jump 34% in Pre-Market Trading — What’s Fueling the Surge?
VolitionRx Share Price Drop: VolitionRx (VNRX) shares fell over 34% in pre-market trading following the announcement of proof-of-concept data from a blinded validation cohort for cancer detection.
New Liquid Biopsy Method: The company revealed a new liquid biopsy method that achieved over 95% sensitivity for stage I & II cancers, with 95% specificity during the blinded validation cohort.
Retail Sentiment: Retail sentiment around VolitionRx trended bullish, with message volumes reported at extremely high levels at the time of writing.
Updates and Corrections: For ongoing updates and corrections related to this story, readers are encouraged to check Stocktwits.
See More
VolitionRx Shares Surge 70% on Breakthrough in Cancer Detection
- Stock Surge: VolitionRx (VNRX) shares soared over 70% in pre-market trading on Wednesday, reflecting strong market enthusiasm for its breakthrough in cancer detection, with the stock poised to breach its 100-day moving average for the first time since October 8, 2025.
- Technological Innovation: The company successfully isolated over 99% pure circulating tumor-derived DNA (ctDNA) from blood samples of cancer patients, addressing a key challenge in liquid biopsy where most circulating DNA typically originates from healthy cells.
- New Method Announcement: VolitionRx submitted an updated manuscript detailing a new two-step method that combines physical sample enrichment with advanced bioinformatics to remove nearly all non-cancer DNA, marking a significant scientific breakthrough in cancer testing and monitoring.
- Scientific Discovery: Chief Scientific Officer Jake Micallef stated that there is almost no CTCF-bound DNA in healthy plasma, and nearly all CTCF-bound DNA in cancer patients' blood is derived from cancer cells, which could represent the biggest scientific breakthrough in cancer testing in recent years.
See More
VolitionRx Unveils New Cancer Detection Technology
- Technological Breakthrough: VolitionRx has successfully isolated and analyzed over 99% pure circulating tumor-derived DNA (ctDNA), a world-first achievement that could revolutionize the liquid biopsy field by enhancing the accuracy and efficiency of early cancer detection.
- Market Potential: The company anticipates a total addressable market (TAM) of approximately $36 billion in multi-cancer early detection (MCED) and minimal residual disease (MRD), indicating significant commercial opportunities and market demand.
- Clinical Validation: The CTCF Capture-Seq™ technology detected 49 cancer cases with no false positives in two independent validation cohorts, showcasing its immense potential in early cancer detection and possibly improving disease management for patients.
- Partnership Opportunities: VolitionRx is actively engaging with several large liquid biopsy and diagnostic companies to accelerate the development and commercialization of this technology, which is expected to enhance the company's competitiveness in the rapidly evolving cancer detection market.
See More
VolitionRx Completes Validation of Nu.Q® Vet Cancer Test with Fujifilm
- Automation Breakthrough: VolitionRx has completed the validation of its Nu.Q® Vet Cancer Test in collaboration with Fujifilm Vet Systems, enabling full automation in central laboratories, which significantly enhances testing efficiency and is expected to meet the increasing demand in the Japanese market.
- Significant Market Potential: Since its launch in July 2024, over 1,700 veterinary hospitals have registered to use the test, indicating a strong demand among Japanese veterinarians for early cancer detection, which is anticipated to create substantial revenue opportunities for Volition.
- Synergistic Technology Platform: The test operates on the same Immunodiagnostic Systems i10® automated analyzer platform used for Volition's human products, showcasing the synergy between human and animal diagnostic technologies, thereby strengthening the company's competitive position in the market.
- Importance of Early Detection: Cancer is the leading cause of death in adult dogs, and the Nu.Q® Vet Cancer Test serves as an accessible and affordable screening tool that aids in early detection, improving health outcomes for dogs, aligning with Volition's mission to enhance life quality through early diagnosis.
See More
